EUVIMEDEUVIMED entdecken
Pragmatische StudieOpen Access

Oral Melatonin in Critically Ill Patients With COVID‐19: A Quasi‐Experimental Pragmatic Trial

Miguel Sánchez-García iD, Jesús A F Tresguerres, Manuel Álvarez-González, Belén de la Hera, Virginia Puebla, Lidia Ybañez, José-Manuel Martínez-Sesmero, Antonio Blesa, Juan-Carlos Martín-Benítez, Fernando Martínez-Sagasti, Paloma González-Arenas, Sara Domingo und 11 weitere

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.70807 ↗

Kurz gefasst

Pragmatische Studie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Miguel Sánchez-García und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care, Hospital Clínico San Carlos, Madrid, Spain. Hauptthemen laut MEDLINE: Melatonin, COVID-19 Drug Treatment, Antioxidants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melatonin has demonstrated antioxidant, anti‐inflammatory, and potential antiviral properties. Its therapeutic role in critically ill COVID‐19 patients admitted to intensive care was underexplored at the start of the pandemic. We conducted a quasi‐experimental, pragmatic study over 4 consecutive uninterrupted time periods alternating control groups receiving standard of care (SoC) with treatment groups receiving SoC plus high‐dose oral bedtime melatonin (50–200 mg) (OBM). The primary endpoint was 90‐day mortality; secondary outcomes included sequential organ failure assessment (SOFA) scores at 4, 7, 14, and 30 days and pre‐defined severe adverse events (SAEs). A total of 335 of 339 consecutive patients with a predicted stay > 48 h were enrolled; 202 received OBM with SoC and 133 received SoC alone. OBM was dispensed during the second ( n = 162) and fourth ( n = 40) study periods after the first ( n = 40) and third ( n = 93) control group periods, respectively. Melatonin therapy was associated with significantly lower 90‐day mortality (20.8% vs. 36.1%, OR 0.46, 95% CI 0.28–0.76). Subjects receiving melatonin had lower SOFA scores on Day 4 and subsequent study visits. SAEs occurred in 84 (41.6%) subjects on OBM and in 80 (60.2%) receiving SoC (risk ratio 0.68, 95% CI 0.54–0.87; p = 0.001). High‐dose oral melatonin was safe and associated with improved clinical outcomes. Further evaluation of melatonin and its potential antiviral effects in future epidemics is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninCOVID-19 Drug TreatmentAntioxidantsHumansMaleFemaleCritical IllnessMiddle AgedAgedAdministration, OralCOVID-19SARS-CoV-2Treatment OutcomeAdultIntensive Care UnitsAntiviral AgentsOrgan Dysfunction Scores

Stichwörter der Autor:innen

COVID‐19ICUOral melatoninSARS‐CoV‐2acute respiratory distress syndromeantiviral effectsmortality

Substanzen

MelatoninAntioxidantsAntiviral Agents

Autor:innen und Institutionen

  • Department of Critical Care, Hospital Clínico San Carlos, Madrid, Spain.
  • Department of Medicine, Medical School, Universidad Complutense Madrid, Madrid, Spain.
  • Department of Physiology, Medical School, Universidad Complutense Madrid, Madrid, Spain.
  • Pharmacy Service, Hospital Clínico San Carlos, Madrid, Spain.
  • Microbiology Service, Hospital Clínico San Carlos, Madrid, Spain.
  • Department of Big Data, PMC-FPS, Regional Ministry of Health and Consumer Affairs, Sevilla, Andalucia, Spain.

ORCID-Profile: Miguel Sánchez-García

Zitieren

APA

Sánchez-García, M., Tresguerres, J. A. F., Álvarez-González, M., Hera, B., Puebla, V., Ybañez, L., Martínez-Sesmero, J. M., Blesa, A., Martín-Benítez, J. C., Martínez-Sagasti, F., González-Arenas, P., Domingo, S., Pardo, C., Maichle, S., Postigo, C., De-Miguel, S., Bringas, M., González-Casanova, R., Yordanov, V., …, & Núñez-Reiz, A. (2026). Oral Melatonin in Critically Ill Patients With COVID‐19: A Quasi‐Experimental Pragmatic Trial. Journal of Medical Virology. https://doi.org/10.1002/jmv.70807

Vancouver

Sánchez-García M, Tresguerres JAF, Álvarez-González M, Hera B, Puebla V, Ybañez L, et al. Oral Melatonin in Critically Ill Patients With COVID‐19: A Quasi‐Experimental Pragmatic Trial. Journal of Medical Virology. 2026. doi:10.1002/jmv.70807

BibTeX
@article{SnchezGarca2026,
  author = {Sánchez-García, Miguel and Tresguerres, Jesús A F and Álvarez-González, Manuel and Hera, Belén de la and Puebla, Virginia and Ybañez, Lidia and Martínez-Sesmero, José-Manuel and Blesa, Antonio and Martín-Benítez, Juan-Carlos and Martínez-Sagasti, Fernando and González-Arenas, Paloma and Domingo, Sara and Pardo, Cándido and Maichle, Silmary and Postigo, Carolina and De-Miguel, Sara and Bringas, María and González-Casanova, Raquel and Yordanov, Viktor and Delgado-Iribarren, Alberto and Culebras, Esther and la-Hoz, Miguel A Armengol-de and Núñez-Reiz, Antonio},
  title = {Oral Melatonin in Critically Ill Patients With COVID‐19: A Quasi‐Experimental Pragmatic Trial},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.70807}
}
Kostenlos starten →